Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPL-TLB100
- Development stage
- Unknown
- Lead developer
- Molecular Pharmacology
- Modality
- Peptides, Small Molecules
- Administration
- Topical
01
Overview
MPL-TLB100 is a topical anti-inflammatory and analgesic drug candidate developed by Molecular Pharmacology (USA) Limited for the treatment of lateral epicondylitis, commonly known as tennis elbow. The drug is the lead candidate based on the proprietary compound tripeptofen (MPL-TL), a tripeptide designed to alleviate the inflammation and tenderness of muscles and tendons on the outside of the elbow. In December 2005, the Medical Ethics Committee of the Curtin University of Technology in Australia approved a human clinical trial for the candidate, marking its entry into clinical development.
- Other names
- tripeptofen
Beyond the preview
Go deeper on MPL-TLB100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPL-TLB100.